APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-GMP Development

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-GMP Development Market Outlook and Growth Opportunities 2026

6 March 2026204 pages

Choose your research edition.

Industry ResearchNon-GMP Development Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-GMP Development Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Non-GMP Development Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-GMP Development Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-GMP Development Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Non-GMP Development market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-GMP Development market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-GMP Development market include Almac, GTP Technology, Alfa Aesar, Sundia-Manufacturing, J-STAR Research Inc., Lonza, AmbioPharm, Velesco and CordenPharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Non-GMP Development market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-GMP Development and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-GMP Development revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Non-GMP Development market.

Non-GMP Development Segment by Company

Almac

GTP Technology

Alfa Aesar

Sundia-Manufacturing

J-STAR Research Inc.

Lonza

AmbioPharm

Velesco

CordenPharma

Piramal Pharma Solutions

Norwich

Aurigene Pharmaceutical Services

Actylis

CARBOGEN AMCIS

GTP Bioways

Symeres

Quotient Sciences

Non-GMP Development Segment by Type

Research Grade

Animal Free Grade

Non-GMP Development Segment by Application

Commercial & Academic

Clinical

Others

Non-GMP Development Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Non-GMP Development status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Non-GMP Development key companies, revenue, market share, and recent developments.

3. To split the Non-GMP Development breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Non-GMP Development market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-GMP Development significant trends, drivers, influence factors in global and regions.

6. To analyze Non-GMP Development competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-GMP Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-GMP Development and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-GMP Development.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-GMP Development industry.

Chapter 3: Detailed analysis of Non-GMP Development company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Non-GMP Development in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Non-GMP Development in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-GMP Development Industry Trends Table 2. Non-GMP Development Industry Drivers Table 3. Non-GMP Development Industry Opportunities and Challenges Table 4. Non-GMP Development Industry Restraints Table 5. Global Non-GMP Development Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-GMP Development Revenue Share by Company (2021-2026) Table 7. Global Non-GMP Development Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Non-GMP Development Key Company Manufacturing Base & Headquarters Table 9. Global Non-GMP Development Company, Product Type & Application Table 10. Global Non-GMP Development Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Non-GMP Development by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Research Grade Table 15. Significant Companies of Animal Free Grade Table 16. Global Non-GMP Development Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Non-GMP Development Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Non-GMP Development Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Non-GMP Development Sales Value Share by Type (2021-2026) Table 20. Global Non-GMP Development Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Commercial & Academic Table 22. Significant Companies of Clinical Table 23. Significant Companies of Others Table 24. Global Non-GMP Development Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Non-GMP Development Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Non-GMP Development Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Non-GMP Development Sales Value Share by Application (2021-2026) Table 28. Global Non-GMP Development Sales Value Share by Application (2027-2032) Table 29. Global Non-GMP Development Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Non-GMP Development Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Non-GMP Development Sales Value Share by Region (2021-2026) Table 32. Global Non-GMP Development Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Non-GMP Development Sales Value Share by Region (2027-2032) Table 34. Global Non-GMP Development Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Non-GMP Development Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Non-GMP Development Sales Value Market Share by Country (2021-2026) Table 37. Global Non-GMP Development Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Non-GMP Development Sales Value Market Share by Country (2027-2032) Table 39. Almac Company Information Table 40. Almac Business Overview Table 41. Almac Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Almac Non-GMP Development Product Portfolio Table 43. Almac Recent Development Table 44. GTP Technology Company Information Table 45. GTP Technology Business Overview Table 46. GTP Technology Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. GTP Technology Non-GMP Development Product Portfolio Table 48. GTP Technology Recent Development Table 49. Alfa Aesar Company Information Table 50. Alfa Aesar Business Overview Table 51. Alfa Aesar Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Alfa Aesar Non-GMP Development Product Portfolio Table 53. Alfa Aesar Recent Development Table 54. Sundia-Manufacturing Company Information Table 55. Sundia-Manufacturing Business Overview Table 56. Sundia-Manufacturing Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sundia-Manufacturing Non-GMP Development Product Portfolio Table 58. Sundia-Manufacturing Recent Development Table 59. J-STAR Research Inc. Company Information Table 60. J-STAR Research Inc. Business Overview Table 61. J-STAR Research Inc. Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. J-STAR Research Inc. Non-GMP Development Product Portfolio Table 63. J-STAR Research Inc. Recent Development Table 64. Lonza Company Information Table 65. Lonza Business Overview Table 66. Lonza Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Lonza Non-GMP Development Product Portfolio Table 68. Lonza Recent Development Table 69. AmbioPharm Company Information Table 70. AmbioPharm Business Overview Table 71. AmbioPharm Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. AmbioPharm Non-GMP Development Product Portfolio Table 73. AmbioPharm Recent Development Table 74. Velesco Company Information Table 75. Velesco Business Overview Table 76. Velesco Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Velesco Non-GMP Development Product Portfolio Table 78. Velesco Recent Development Table 79. CordenPharma Company Information Table 80. CordenPharma Business Overview Table 81. CordenPharma Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. CordenPharma Non-GMP Development Product Portfolio Table 83. CordenPharma Recent Development Table 84. Piramal Pharma Solutions Company Information Table 85. Piramal Pharma Solutions Business Overview Table 86. Piramal Pharma Solutions Non-GMP Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Piramal Pharma Solutions Non-GMP Development Product Portfolio Table 88. Piramal Pharma Solutions Recent Development Table 89. Norwich Company Information Table 90. Norwich Business Overview Table 91. Norwich Non-GMP Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Norwich Non-GMP Development Product Portfolio Table 93. Norwich Recent Development Table 94. Aurigene Pharmaceutical Services Company Information Table 95. Aurigene Pharmaceutical Services Business Overview Table 96. Aurigene Pharmaceutical Services Non-GMP Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Aurigene Pharmaceutical Services Non-GMP Development Product Portfolio Table 98. Aurigene Pharmaceutical Services Recent Development Table 99. Actylis Company Information Table 100. Actylis Business Overview Table 101. Actylis Non-GMP Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Actylis Non-GMP Development Product Portfolio Table 103. Actylis Recent Development Table 104. CARBOGEN AMCIS Company Information Table 105. CARBOGEN AMCIS Business Overview Table 106. CARBOGEN AMCIS Non-GMP Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. CARBOGEN AMCIS Non-GMP Development Product Portfolio Table 108. CARBOGEN AMCIS Recent Development Table 109. GTP Bioways Company Information Table 110. GTP Bioways Business Overview Table 111. GTP Bioways Non-GMP Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. GTP Bioways Non-GMP Development Product Portfolio Table 113. GTP Bioways Recent Development Table 114. Symeres Company Information Table 115. Symeres Business Overview Table 116. Symeres Non-GMP Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Symeres Non-GMP Development Product Portfolio Table 118. Symeres Recent Development Table 119. Quotient Sciences Company Information Table 120. Quotient Sciences Business Overview Table 121. Quotient Sciences Non-GMP Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Quotient Sciences Non-GMP Development Product Portfolio Table 123. Quotient Sciences Recent Development Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Non-GMP Development Product Image Figure 2. Global Non-GMP Development Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-GMP Development Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-GMP Development Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Research Grade Image Figure 8. Animal Free Grade Image Figure 9. Global Non-GMP Development Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Non-GMP Development Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Non-GMP Development Sales Value Share by Type (2021-2032) Figure 12. Commercial & Academic Image Figure 13. Clinical Image Figure 14. Others Image Figure 15. Global Non-GMP Development Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Non-GMP Development Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Non-GMP Development Sales Value Share by Application (2021-2032) Figure 18. Global Non-GMP Development Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Non-GMP Development Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Non-GMP Development Sales Value (2021-2032) & (US$ Million) Figure 21. North America Non-GMP Development Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Non-GMP Development Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Non-GMP Development Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Non-GMP Development Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Non-GMP Development Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Non-GMP Development Sales Value (2021-2032) & (US$ Million) Figure 27. South America Non-GMP Development Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Non-GMP Development Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Non-GMP Development Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Non-GMP Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Non-GMP Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Non-GMP Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Research Grade
  • Animal Free Grade
Applications
  • Commercial & Academic
  • Clinical
  • Others
Companies covered
  • Almac
  • GTP Technology
  • Alfa Aesar
  • Sundia-Manufacturing
  • J-STAR Research Inc.
  • Lonza
  • AmbioPharm
  • Velesco
  • CordenPharma
  • Piramal Pharma Solutions
  • Norwich
  • Aurigene Pharmaceutical Services
  • Actylis
  • CARBOGEN AMCIS
  • GTP Bioways
  • Symeres
  • Quotient Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Non-GMP Development Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Non-GMP Development Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Non-GMP Development Market Dynamics
  1. 2.1 Non-GMP Development Industry Trends
  2. 2.2 Non-GMP Development Industry Drivers
  3. 2.3 Non-GMP Development Industry Opportunities and Challenges
  4. 2.4 Non-GMP Development Industry Restraints
3 Non-GMP Development Market by Company
  1. 3.1 Global Non-GMP Development Company Revenue Ranking in 2025
  2. 3.2 Global Non-GMP Development Revenue by Company (2021-2026)
  3. 3.3 Global Non-GMP Development Company Ranking (2024-2026)
  4. 3.4 Global Non-GMP Development Company Manufacturing Base and Headquarters
  5. 3.5 Global Non-GMP Development Company Product Type and Application
  6. 3.6 Global Non-GMP Development Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Non-GMP Development Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Non-GMP Development Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Non-GMP Development Market by Type
  1. 4.1 Non-GMP Development Type Introduction
  2. 4.1.1 Research Grade
  3. 4.1.2 Animal Free Grade
  4. 4.2 Global Non-GMP Development Sales Value by Type
  5. 4.2.1 Global Non-GMP Development Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Non-GMP Development Sales Value by Type (2021-2032)
  7. 4.2.3 Global Non-GMP Development Sales Value Share by Type (2021-2032)
5 Non-GMP Development Market by Application
  1. 5.1 Non-GMP Development Application Introduction
  2. 5.1.1 Commercial & Academic
  3. 5.1.2 Clinical
  4. 5.1.3 Others
  5. 5.2 Global Non-GMP Development Sales Value by Application
  6. 5.2.1 Global Non-GMP Development Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-GMP Development Sales Value by Application (2021-2032)
  8. 5.2.3 Global Non-GMP Development Sales Value Share by Application (2021-2032)
6 Non-GMP Development Regional Value Analysis
  1. 6.1 Global Non-GMP Development Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-GMP Development Sales Value by Region (2021-2032)
  3. 6.2.1 Global Non-GMP Development Sales Value by Region: 2021-2026
  4. 6.2.2 Global Non-GMP Development Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Non-GMP Development Sales Value (2021-2032)
  7. 6.3.2 North America Non-GMP Development Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Non-GMP Development Sales Value (2021-2032)
  10. 6.4.2 Europe Non-GMP Development Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Non-GMP Development Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Non-GMP Development Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Non-GMP Development Sales Value (2021-2032)
  16. 6.6.2 South America Non-GMP Development Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Non-GMP Development Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Non-GMP Development Sales Value Share by Country, 2025 VS 2032
7 Non-GMP Development Country-level Value Analysis
  1. 7.1 Global Non-GMP Development Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-GMP Development Sales Value by Country (2021-2032)
  3. 7.2.1 Global Non-GMP Development Sales Value by Country (2021-2026)
  4. 7.2.2 Global Non-GMP Development Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Non-GMP Development Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Non-GMP Development Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Non-GMP Development Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Non-GMP Development Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Non-GMP Development Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Non-GMP Development Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Non-GMP Development Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Non-GMP Development Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Non-GMP Development Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Non-GMP Development Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Non-GMP Development Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Non-GMP Development Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Non-GMP Development Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Non-GMP Development Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Non-GMP Development Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Non-GMP Development Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Non-GMP Development Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Non-GMP Development Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Non-GMP Development Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Non-GMP Development Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Non-GMP Development Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Non-GMP Development Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Non-GMP Development Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Non-GMP Development Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Non-GMP Development Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Non-GMP Development Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Non-GMP Development Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Non-GMP Development Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Non-GMP Development Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Non-GMP Development Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Non-GMP Development Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Almac
  2. 8.1.1 Almac Company Information
  3. 8.1.2 Almac Business Overview
  4. 8.1.3 Almac Non-GMP Development Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Almac Non-GMP Development Product Portfolio
  6. 8.1.5 Almac Recent Developments
  7. 8.2 GTP Technology
  8. 8.2.1 GTP Technology Company Information
  9. 8.2.2 GTP Technology Business Overview
  10. 8.2.3 GTP Technology Non-GMP Development Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GTP Technology Non-GMP Development Product Portfolio
  12. 8.2.5 GTP Technology Recent Developments
  13. 8.3 Alfa Aesar
  14. 8.3.1 Alfa Aesar Company Information
  15. 8.3.2 Alfa Aesar Business Overview
  16. 8.3.3 Alfa Aesar Non-GMP Development Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Alfa Aesar Non-GMP Development Product Portfolio
  18. 8.3.5 Alfa Aesar Recent Developments
  19. 8.4 Sundia-Manufacturing
  20. 8.4.1 Sundia-Manufacturing Company Information
  21. 8.4.2 Sundia-Manufacturing Business Overview
  22. 8.4.3 Sundia-Manufacturing Non-GMP Development Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sundia-Manufacturing Non-GMP Development Product Portfolio
  24. 8.4.5 Sundia-Manufacturing Recent Developments
  25. 8.5 J-STAR Research Inc.
  26. 8.5.1 J-STAR Research Inc. Company Information
  27. 8.5.2 J-STAR Research Inc. Business Overview
  28. 8.5.3 J-STAR Research Inc. Non-GMP Development Revenue and Gross Margin (2021-2026)
  29. 8.5.4 J-STAR Research Inc. Non-GMP Development Product Portfolio
  30. 8.5.5 J-STAR Research Inc. Recent Developments
  31. 8.6 Lonza
  32. 8.6.1 Lonza Company Information
  33. 8.6.2 Lonza Business Overview
  34. 8.6.3 Lonza Non-GMP Development Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lonza Non-GMP Development Product Portfolio
  36. 8.6.5 Lonza Recent Developments
  37. 8.7 AmbioPharm
  38. 8.7.1 AmbioPharm Company Information
  39. 8.7.2 AmbioPharm Business Overview
  40. 8.7.3 AmbioPharm Non-GMP Development Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AmbioPharm Non-GMP Development Product Portfolio
  42. 8.7.5 AmbioPharm Recent Developments
  43. 8.8 Velesco
  44. 8.8.1 Velesco Company Information
  45. 8.8.2 Velesco Business Overview
  46. 8.8.3 Velesco Non-GMP Development Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Velesco Non-GMP Development Product Portfolio
  48. 8.8.5 Velesco Recent Developments
  49. 8.9 CordenPharma
  50. 8.9.1 CordenPharma Company Information
  51. 8.9.2 CordenPharma Business Overview
  52. 8.9.3 CordenPharma Non-GMP Development Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CordenPharma Non-GMP Development Product Portfolio
  54. 8.9.5 CordenPharma Recent Developments
  55. 8.10 Piramal Pharma Solutions
  56. 8.10.1 Piramal Pharma Solutions Company Information
  57. 8.10.2 Piramal Pharma Solutions Business Overview
  58. 8.10.3 Piramal Pharma Solutions Non-GMP Development Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Piramal Pharma Solutions Non-GMP Development Product Portfolio
  60. 8.10.5 Piramal Pharma Solutions Recent Developments
  61. 8.11 Norwich
  62. 8.11.1 Norwich Company Information
  63. 8.11.2 Norwich Business Overview
  64. 8.11.3 Norwich Non-GMP Development Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Norwich Non-GMP Development Product Portfolio
  66. 8.11.5 Norwich Recent Developments
  67. 8.12 Aurigene Pharmaceutical Services
  68. 8.12.1 Aurigene Pharmaceutical Services Company Information
  69. 8.12.2 Aurigene Pharmaceutical Services Business Overview
  70. 8.12.3 Aurigene Pharmaceutical Services Non-GMP Development Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Aurigene Pharmaceutical Services Non-GMP Development Product Portfolio
  72. 8.12.5 Aurigene Pharmaceutical Services Recent Developments
  73. 8.13 Actylis
  74. 8.13.1 Actylis Company Information
  75. 8.13.2 Actylis Business Overview
  76. 8.13.3 Actylis Non-GMP Development Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Actylis Non-GMP Development Product Portfolio
  78. 8.13.5 Actylis Recent Developments
  79. 8.14 CARBOGEN AMCIS
  80. 8.14.1 CARBOGEN AMCIS Company Information
  81. 8.14.2 CARBOGEN AMCIS Business Overview
  82. 8.14.3 CARBOGEN AMCIS Non-GMP Development Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CARBOGEN AMCIS Non-GMP Development Product Portfolio
  84. 8.14.5 CARBOGEN AMCIS Recent Developments
  85. 8.15 GTP Bioways
  86. 8.15.1 GTP Bioways Company Information
  87. 8.15.2 GTP Bioways Business Overview
  88. 8.15.3 GTP Bioways Non-GMP Development Revenue and Gross Margin (2021-2026)
  89. 8.15.4 GTP Bioways Non-GMP Development Product Portfolio
  90. 8.15.5 GTP Bioways Recent Developments
  91. 8.16 Symeres
  92. 8.16.1 Symeres Company Information
  93. 8.16.2 Symeres Business Overview
  94. 8.16.3 Symeres Non-GMP Development Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Symeres Non-GMP Development Product Portfolio
  96. 8.16.5 Symeres Recent Developments
  97. 8.17 Quotient Sciences
  98. 8.17.1 Quotient Sciences Company Information
  99. 8.17.2 Quotient Sciences Business Overview
  100. 8.17.3 Quotient Sciences Non-GMP Development Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Quotient Sciences Non-GMP Development Product Portfolio
  102. 8.17.5 Quotient Sciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst